Although BRAF and mitogen-activated protein kinase (MEK) inhibitors has improved current situation of melanoma therapy, challenges still remain regarding how to overcome drug resistance and meet the demand of more effective targeted therapies [10]. Here, BRAF is linked to melanoma.